Table 2 Summary of the clinical characteristics of the patient groups included in the verification cohort
Chemoresistant (n = 25) | Chemosensitive (n = 63) | |
|---|---|---|
Age (years) | ||
Average (range) | 63 (49–81) | 59 (37–84) |
Menopausal status (n, %) | ||
Premenopausal | 1 (4%) | 18 (29%) |
Postmenopausal | 24 (96%) | 45 (71%) |
Stage (n, %) | ||
IIIA | 0 | 2 (3%) |
IIIB | 1 (4%) | 6 (10%) |
IIIC | 16 (64%) | 45 (71%) |
IVA | 3 (12%) | 4 (6%) |
IVB | 5 (20%) | 6 (10%) |
Serum CA125 levels at diagnosis (U/mL) | ||
Average (range) | 2246 (161–10,548) | 1385 (20–19,007) |
TFIp (months) | ||
Average (range) | 3 (1–5) | 13 (6–63) |
Primary treatment (n, %) | ||
Cytoreductive surgery | 7 (28%) | 44 (70%) |
Neoadjuvant chemotherapy | 18 (72%) | 19 (30%) |
Status (n, %) | ||
Alive | 0 | 31 (49%) |
Dead | 25 (100%) | 32 (51%) |